Case file
QP Pharmachem (Punjab): Guaifenesin Syrup TG
Last checked 1 October 2026
QP Pharmachem, a manufacturer in Punjab, made Guaifenesin Syrup TG, marketed by Trillium Pharma of Haryana, which was found to contain unacceptable levels of diethylene glycol and ethylene glycol in samples from the Marshall Islands and the Federated States of Micronesia. The WHO issued Medical Product Alert N°4/2023 on 25 April 2023. No deaths were reported in the alert. Punjab's drug authorities were reported to have acted against the firm; the nature and current status of that action have not been published.
Status as of 1 October 2026
WHO Medical Product Alert N°4/2023: Substandard (contaminated) syrup medicines
Scope. A record here does not by itself mean a product or company is unsafe or banned today. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Affected products and batches
| Product | Batch | Note |
|---|---|---|
| Guaifenesin Syrup TG | Not stated | DEG/EG contamination per WHO testing |
Current status
Product subject to WHO alert; state regulatory action against QP Pharmachem reported but unverified as of 1 Oct 2026. The syrup was exported and not known to be sold in India.
What to do if you have this product
Step 1
Do not use Guaifenesin Syrup TG of any batch.
Step 2
Importers in the Pacific should follow their national regulator's recall instructions.
Sources
- WHO Medical Product Alert N°4/2023: Substandard (contaminated) syrup medicinesWHOWorld Health Organization · 25 April 2023
- WHO: Full list of medical product alertsWHOWorld Health Organization